Enlivex Therapeutics
ENLV

$1.51

0.67%

Market Cap: $32.3M

About: Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Employees: 49

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

145% more call options, than puts

Call options by funds: $54K | Put options by funds: $22K

96% more capital invested

Capital invested by funds: $1.51M [Q1] → $2.96M (+$1.45M) [Q2]

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

13% more funds holding

Funds holding: 15 [Q1] → 17 (+2) [Q2]

7.84% more ownership

Funds ownership: 2.14% [Q1] → 9.99% (+7.84%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

297%

upside

Avg. target

$9.50

529%

upside

High target

$13

761%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 108 / 251 met price target	297%upside $6	Buy Reiterated	9 Sept 2024
EF Hutton Jason Kolbert 40% 1-year accuracy 12 / 30 met price target	761%upside $13	Buy Initiated	27 Aug 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy

Enlivex Therapeutics (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / August 30, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Enlivex Therapeutics Ltd. (Nasdaq:ENLV) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 31, at 7 p.m.

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m.

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last resort” Three-month data readout showed a significant reduction in pain and a favorable safety profile Pain reduction: patients reported an average pain reduction of 64% from baseline Complete Pain Resolution: 33% of patients reported complete pain relief, from an average pain level of 9 to a pain level of 0; pain scale used in the study ranged from 0 (no pain) to 10 (maximum pain) Avoidance of Surgery: 89% of patients did not proceed with knee replacement surgery at three months post-injection Safety: No severe adverse events related to Allocetra™ were reported Ness-Ziona, Israel, June 17, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today released a positive interim data readout from a Phase I/II investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis who had been indicated for knee replacement surgery.

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants, for aggregate gross proceeds of approximately $5.0 million.

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants.

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company's multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health (IMOH) in January.

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Zacks Investment Research

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will host a conference call and webcast on April 12, 2024, at 8:30am ET (15:30 IL time) to discuss topline results from its Phase II trial of Allocetra™ in patients with sepsis, in which 120 patients enrolled. During the call, members of Enlivex's leadership team will discuss the results. A live Q&A session will follow the Company's prepared remarks.

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive indication of effect and safety results from its Phase II study of Allocetra™ in patients with sepsis, in which 120 patients enrolled.

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

See News Rankings